Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Verrica Pharmaceuticals Inc (VRCA)

Verrica Pharmaceuticals Inc (VRCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 356,726
  • Shares Outstanding, K 25,775
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,650 K
  • 60-Month Beta 4.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.30
  • Prior Year -0.30
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.00 +0.92%
on 12/03/19
18.67 -29.73%
on 11/26/19
-2.07 (-13.63%)
since 11/08/19
3-Month
10.05 +30.55%
on 09/10/19
18.67 -29.73%
on 11/26/19
+2.62 (+24.95%)
since 09/09/19
52-Week
6.44 +103.73%
on 12/20/18
18.67 -29.73%
on 11/26/19
+2.87 (+28.00%)
since 12/07/18

Most Recent Stories

More News
Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people...

VRCA : 13.12 (-5.20%)
Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company's Board of Directors. Mr. Oclassen passed away on November...

VRCA : 13.12 (-5.20%)
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

-- VP-102 achieved positive results in the COVE-1 study on the endpoint of complete clearance of all common warts at Day 84 (primary endpoint) as well as Day 147 (exploratory endpoint)

VRCA : 13.12 (-5.20%)
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people...

VRCA : 13.12 (-5.20%)
Verrica Pharmaceuticals Announces Leadership Team Update

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people...

BMY : 61.28 (+2.22%)
NVO : 56.69 (-0.09%)
SBBP : 1.77 (-2.21%)
VRCA : 13.12 (-5.20%)
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia

FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.

AZN : 47.77 (+0.19%)
SPPI : 10.29 (+4.57%)
FGEN : 47.76 (+0.78%)
VRCA : 13.12 (-5.20%)
Will Verrica Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.

VRCA : 13.12 (-5.20%)
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD

FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.

AZN : 47.77 (+0.19%)
SPPI : 10.29 (+4.57%)
FGEN : 47.76 (+0.78%)
VRCA : 13.12 (-5.20%)
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX : 113.75 (-2.62%)
GNCA : 2.15 (unch)
REPH : 17.01 (+3.09%)
ZTS : 121.23 (-0.40%)
CPRX : 4.50 (-3.64%)
FLXN : 20.16 (+3.23%)
VRCA : 13.12 (-5.20%)
Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people...

VRCA : 13.12 (-5.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade VRCA with:

Business Summary

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States.

See More

Key Turning Points

2nd Resistance Point 14.46
1st Resistance Point 13.79
Last Price 13.12
1st Support Level 12.77
2nd Support Level 12.42

See More

52-Week High 18.67
Fibonacci 61.8% 14.00
Last Price 13.12
Fibonacci 50% 12.56
Fibonacci 38.2% 11.11
52-Week Low 6.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar